Biomarker Analysis Services for Muscular Dystrophy
Protheragen offers specialized biomarker analysis services tailored exclusively for Muscular Dystrophy drug discovery and preclinical development. Our comprehensive biomarker panel is designed to facilitate a deeper understanding of the molecular and cellular mechanisms underlying Muscular Dystrophy, supporting the advancement of novel therapeutic strategies. All services are strictly limited to research applications in drug discovery and do not encompass clinical diagnostic services.
Effective therapeutic intervention begins with the identification and characterization of robust biomarkers that reflect disease pathophysiology. Protheragen’s biomarker discovery services leverage advanced screening methodologies to recognize molecular signatures relevant to Muscular Dystrophy. Our process includes high-throughput screening, initial candidate identification, and rigorous validation steps to ensure the reliability and relevance of discovered biomarkers within the preclinical research context.
Multi Omics: We employ cutting-edge multi-omics technologies—including genomics, transcriptomics, and proteomics—to provide a comprehensive study of biological systems implicated in Muscular Dystrophy. By integrating data from DNA, RNA, protein, and metabolite analyses, we enable the identification of novel biomarkers associated with key disease pathways such as muscle fiber integrity, extracellular matrix remodeling, apoptosis, and neuromuscular signaling. This holistic approach supports the elucidation of complex molecular networks involved in Muscular Dystrophy.
Candidate Validation: Our validation strategies encompass a combination of in vitro, ex vivo, and in vivo models to assess the relevance of candidate biomarkers to Muscular Dystrophy pathophysiology. Preliminary screening processes are conducted using molecular and cellular assays to confirm association with disease mechanisms. Criteria for prioritizing promising candidates include specificity to muscle tissue, correlation with disease progression or severity, and potential utility in monitoring therapeutic response during preclinical development.
Diverse Technological Platforms: Protheragen develops custom biomarker assays adaptable to a wide range of technological platforms, ensuring compatibility with specific research requirements. Our platform portfolio includes immunoassays, mass spectrometry, flow cytometry, molecular diagnostic systems, and advanced histopathology and imaging modalities, all optimized for sensitivity, specificity, and scalability.
Immunoassays: We design and implement ELISA, chemiluminescent, and multiplex immunoassays for quantitative detection of protein biomarkers in biological samples.
Mass Spectrometry: Our LC-MS/MS workflows enable precise quantification and characterization of peptides and proteins relevant to Muscular Dystrophy.
Flow Cytometry: We utilize flow cytometry for high-throughput cell surface and intracellular marker analysis, supporting detailed cellular phenotyping.
Molecular Diagnostics: Custom molecular assays, including qPCR and digital PCR, allow for the detection and quantification of gene and transcript biomarkers.
Histopathology And Imaging: We employ histopathological staining and advanced imaging techniques to visualize biomarker distribution and tissue architecture in muscle biopsies.
Rigorous Method Validation: All analytical methods undergo rigorous validation in accordance with established research guidelines. Performance characteristics such as sensitivity, specificity, accuracy, precision, and linearity are systematically evaluated. Comprehensive quality control measures, including the use of appropriate standards and controls, are implemented to ensure data integrity and reproducibility throughout the assay lifecycle.
Our quantitative analysis capabilities enable precise measurement of biomarker levels across a range of sample types and experimental conditions. We utilize validated calibration standards, internal controls, and robust statistical analyses to ensure the reliability of quantitative data generated during preclinical research.
Sample Analysis: Protheragen processes a variety of sample types—including muscle tissue, serum, plasma, and cultured cells—using standardized protocols to preserve sample integrity. Each analysis is conducted under stringent quality assurance measures, with careful documentation and adherence to best practices to minimize variability and ensure reproducibility.
High Throughput Capabilities: We offer high-throughput analytical platforms capable of multiplexed biomarker detection, allowing simultaneous analysis of multiple targets within limited sample volumes. This approach enhances efficiency, conserves valuable research samples, and accelerates data acquisition for large-scale preclinical studies.
| Gene Target | Biological Function | Application as a Biomarker |
|---|---|---|
| androgen receptor (AR) | The androgen receptor (AR) is a type of nuclear hormone receptor that is activated by binding androgens, such as testosterone and dihydrotestosterone. Upon ligand binding, AR undergoes a conformational change, translocates to the nucleus, and binds to specific DNA sequences known as androgen response elements to regulate the transcription of target genes. These genes are involved in the development and maintenance of male sexual characteristics, reproductive function, and the regulation of cellular growth and differentiation in various tissues, including the prostate, muscle, and bone. | Androgen receptor expression and status are utilized in clinical and research settings as biomarkers, particularly in prostate cancer and certain subtypes of breast cancer. In prostate cancer, AR expression is routinely assessed to inform therapeutic strategies, as many tumors are initially androgen-dependent. AR status can also provide information on tumor biology and potential responsiveness to androgen deprivation therapies. In breast cancer, AR expression is investigated to characterize tumor subtypes and may have prognostic or predictive implications in specific contexts. |
| caspase 3 (CASP3) | Caspase 3 (CASP3) is a cysteine-aspartic acid protease that plays a central role in the execution phase of apoptosis. It is synthesized as an inactive proenzyme that is cleaved to form an active enzyme in response to pro-apoptotic signals. Once activated, CASP3 cleaves a variety of cellular substrates, leading to the morphological and biochemical changes characteristic of apoptosis, such as DNA fragmentation, chromatin condensation, and cell shrinkage. CASP3 is also involved in non-apoptotic processes, including cell differentiation and inflammation, but its primary function is the orchestration of programmed cell death. | CASP3 is commonly used as a biomarker for apoptosis in both clinical and research settings. The presence of activated or cleaved CASP3 in tissues or cells is indicative of apoptotic activity and is frequently assessed by immunohistochemistry, Western blotting, or activity assays. It has been applied in studies of cancer, neurodegenerative diseases, and tissue injury to evaluate the extent of apoptosis. In oncology, CASP3 expression and activation have been investigated in relation to tumor progression, response to therapy, and prognosis. |
| collagen type VI alpha 1 chain (COL6A1) | Collagen type VI alpha 1 chain (COL6A1) encodes one of the three alpha chains that constitute type VI collagen, a structural protein of the extracellular matrix. Type VI collagen forms beaded microfibrils that provide structural support and stability to tissues, particularly in skeletal muscle, skin, and connective tissue. COL6A1 plays a key role in cell adhesion, anchoring cells to the extracellular matrix, and contributes to tissue integrity and elasticity. Mutations in COL6A1 have been associated with several muscular dystrophies, highlighting its importance in muscle function and maintenance. | COL6A1 expression and protein levels have been investigated as biomarkers in various contexts. In muscular dystrophies such as Bethlem myopathy and Ullrich congenital muscular dystrophy, altered COL6A1 levels may reflect disease presence and progression. Additionally, upregulation of COL6A1 has been reported in certain cancers, including breast and gastric cancer, where its expression may correlate with tumor progression, invasion, or prognosis. Its utility as a biomarker is primarily based on its differential expression in pathological versus normal tissues. |
| dystrophin (DMD) | Dystrophin is a large cytoskeletal protein encoded by the DMD gene, primarily expressed in skeletal and cardiac muscle. It localizes to the inner surface of the muscle cell membrane (sarcolemma), where it is a key component of the dystrophin-glycoprotein complex. Dystrophin provides structural stability to muscle fibers by linking the actin cytoskeleton to the extracellular matrix via associated membrane proteins. This linkage helps maintain membrane integrity during muscle contraction and protects muscle cells from mechanical stress and injury. | Dystrophin is used as a biomarker in the diagnosis and assessment of Duchenne and Becker muscular dystrophies. Its presence, absence, or abnormal expression in muscle tissue, as determined by immunohistochemistry or Western blot analysis, aids in distinguishing between these conditions and evaluating disease severity. Quantification of dystrophin levels is also applied in monitoring response to experimental therapies aimed at restoring or increasing dystrophin expression. |
| integrin subunit alpha 7 (ITGA7) | Integrin subunit alpha 7 (ITGA7) is a member of the integrin alpha chain family of cell surface receptors. Integrins are heterodimeric transmembrane proteins composed of alpha and beta subunits that mediate cell-extracellular matrix (ECM) and cell-cell interactions. ITGA7 primarily pairs with the beta 1 subunit (ITGB1) to form the integrin α7β1 complex, which serves as a receptor for laminin isoforms in the basement membrane. This interaction plays a key role in the adhesion, migration, and structural integrity of skeletal and cardiac muscle cells. ITGA7 is involved in myogenesis, muscle regeneration, and maintenance of muscle tissue architecture. Additionally, it contributes to signal transduction pathways that influence cell proliferation, differentiation, and survival. | ITGA7 has been investigated as a biomarker in several contexts. Altered expression of ITGA7 has been reported in various muscular dystrophies and other muscle disorders, where it may reflect changes in muscle regeneration or pathology. In oncology, ITGA7 expression patterns have been studied in relation to tumor progression, metastasis, and prognosis in certain cancers, including prostate, lung, and hepatocellular carcinoma. Its expression may be assessed in tissue samples to provide information about disease status or biological behavior, depending on the clinical context. |
| myosin heavy chain 2 (MYH2) | MYH2 encodes the myosin heavy chain 2 protein, which is a major component of type IIa (fast-twitch oxidative) skeletal muscle fibers. Myosin heavy chains are motor proteins that interact with actin filaments to generate force and facilitate muscle contraction through ATP hydrolysis. MYH2 plays a critical role in determining the contractile and metabolic properties of muscle fibers, contributing to muscle strength, speed of contraction, and endurance. It is predominantly expressed in adult skeletal muscle and is essential for normal muscle structure and function. | MYH2 expression is used as a molecular marker to identify and characterize type IIa fast-twitch muscle fibers in muscle biopsies and histological analyses. Alterations in MYH2 expression or mutations in the MYH2 gene have been associated with certain myopathies, such as myosin storage myopathy and autosomal dominant myopathy with congenital joint contractures. Assessment of MYH2 can aid in the classification of muscle fiber types, evaluation of muscle remodeling, and differentiation of muscle disorders in clinical and research settings. |
| myostatin (MSTN) | Myostatin (MSTN), also known as growth differentiation factor 8 (GDF-8), is a member of the transforming growth factor-beta (TGF-β) superfamily. It is a secreted protein that functions primarily as a negative regulator of skeletal muscle growth. Myostatin inhibits myogenesis by suppressing the proliferation and differentiation of myoblasts, thereby limiting muscle tissue growth. Loss-of-function mutations in the MSTN gene result in increased muscle mass due to reduced inhibition of muscle development. Myostatin is expressed predominantly in skeletal muscle tissue, but lower levels are also found in adipose tissue and the heart. | Myostatin levels have been measured in serum, plasma, and muscle tissue as a biomarker for muscle mass, muscle wasting, and related conditions. Altered myostatin expression or circulating concentrations have been associated with muscle atrophy in diseases such as muscular dystrophy, sarcopenia, cachexia, and chronic heart failure. Myostatin has been investigated as a biomarker to monitor disease progression, assess therapeutic response, and evaluate muscle health in various clinical and research contexts. |
| ryanodine receptor 1 (RYR1) | Ryanodine receptor 1 (RYR1) is a calcium release channel located primarily in the membrane of the sarcoplasmic reticulum in skeletal muscle cells. It plays a central role in excitation-contraction coupling by mediating the rapid release of calcium ions from the sarcoplasmic reticulum into the cytoplasm in response to membrane depolarization. This calcium release triggers muscle contraction. RYR1 is regulated by various factors, including voltage sensors, accessory proteins, and post-translational modifications, and mutations in RYR1 can disrupt normal calcium homeostasis, affecting muscle function. | RYR1 is used as a biomarker in the context of certain skeletal muscle disorders, particularly malignant hyperthermia susceptibility (MHS) and various congenital myopathies such as central core disease. Genetic testing for pathogenic variants in the RYR1 gene can aid in the diagnosis or risk assessment of these conditions. Additionally, altered expression or function of RYR1 may be evaluated in muscle biopsies or molecular assays as part of the diagnostic process for related neuromuscular disorders. |
| survival of motor neuron 1, telomeric (SMN1) | The survival of motor neuron 1, telomeric (SMN1) gene encodes the SMN protein, which is essential for the biogenesis of small nuclear ribonucleoproteins (snRNPs), key components of the spliceosome involved in pre-mRNA splicing. SMN1 is ubiquitously expressed and plays a critical role in the assembly of snRNP complexes by facilitating the transfer of Sm proteins to snRNA. The SMN protein is also implicated in axonal transport and maintenance of motor neurons. Deficiency or loss of function of SMN1 leads to reduced levels of functional SMN protein, which predominantly affects motor neurons and is the main genetic cause of spinal muscular atrophy (SMA). | SMN1 is used in molecular diagnostics to detect deletions or mutations associated with spinal muscular atrophy (SMA). The presence or absence of SMN1 gene copies, as determined by genetic testing, serves as a biomarker for SMA diagnosis and carrier screening. Quantitative assessment of SMN1 copy number is also applied in prenatal and preimplantation genetic testing for individuals at risk of SMA. |
| survival of motor neuron 2, centromeric (SMN2) | The survival of motor neuron 2, centromeric (SMN2) gene encodes the SMN protein, which is involved in the assembly of small nuclear ribonucleoproteins (snRNPs) essential for pre-mRNA splicing. SMN2 is nearly identical to SMN1, but due to a critical nucleotide difference, most transcripts from SMN2 undergo alternative splicing that results in the exclusion of exon 7, producing a truncated, less stable, and less functional SMN protein. Only a small proportion of SMN2 transcripts produce full-length, functional SMN protein. The SMN protein is ubiquitously expressed and is particularly important for the maintenance and survival of motor neurons. | SMN2 is used as a biomarker in the context of spinal muscular atrophy (SMA). The gene copy number of SMN2 is assessed to help predict disease severity, as increased SMN2 copy number is generally associated with milder phenotypes of SMA. Quantification of SMN2 copy number is employed in clinical and research settings to assist in prognosis, stratification of patients, and monitoring response to therapies that modulate SMN2 expression or splicing. |
Explore Research Opportunities with Protheragen. Our biomarker research services for Muscular Dystrophy leverage advanced analytical platforms and multi-omics technologies to support exploratory research and drug discovery in preclinical development stages. The biomarkers discussed herein are research targets only and are not claimed as validated or mandatory for any specific application. Protheragen maintains a strict focus on preclinical research and does not provide clinical diagnostic services. We invite collaboration with partners seeking objective, scientifically rigorous support for biomarker exploration in Muscular Dystrophy.
We invite you to connect with Protheragen to discuss collaborative opportunities in biomarker research for Muscular Dystrophy. Our approach is exploratory and research-focused, emphasizing scientific exchange and objective inquiry without claims of biomarker validation or necessity. Let’s advance the understanding of Muscular Dystrophy together through collaborative research.
Make Order
Experimental Scheme
Implementation
Conclusion
